Kitasato University Medical Center
In research, Kitasato University Medical Center stands highest in Medicine (#16,948 of 17,978 worldwide) and Health Sciences (#19,564 of 20,462 worldwide), over all time.
- World rank, all time
- #34,212 of 42,892
- Rank in Japan
- #1,460 of 2,112
- Research works
- 290 ▲ 26% vs 2013–17
- Citations
- 8k 27.7 per fractional work
- Top-10% rate
- 5.2% record average 16.5%
- Open access
- 53% world 28%
What is Kitasato University Medical Center known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #16,948 of 17,978 | 6.2% | 196 | |
| Health SciencesDomain | #19,564 of 20,462 | 6.4% | 203 |
Each strip is that field’s whole ranked pool, with the notch where Kitasato University Medical Center sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.1×. Every wedge is a field page.
- Medicine 4.1×
- Pharmacology, Toxicology and Pharmaceutics 2.9×
- Neuroscience 1.9×
- Immunology and Microbiology 1.8×
- Biochemistry, Genetics and Molecular Biology 1.5×
- Nursing 0.9×
- Health Professions 0.7×
- Psychology 0.5×
- Computer Science 0.2×
- Mathematics 0.2×
- Engineering 0.1×
- Agricultural and Biological Sciences 0.1×
- Environmental Science 0.0×
- Social Sciences 0.0×
Which keywords describe research at Kitasato University Medical Center?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Epidemiology, Inflammation, Clinical Trials, Targeted Therapy, Prognostic Factors and Treatment.
- Tumor Markers
- Thrombosis
- Lung Cancer
- Prognosis
- Pathophysiology
- Diabetes
- Gemcitabine
- Pancreatic Cancer
- Pathogenesis
- EGFR Mutations
- Surgical Management
- Adjuvant Therapy
- Guidelines
- Immune Response
- Tumor Microenvironment
- Quality of Life
- Prognostic Factors
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Epidemiology
- Inflammation
- Clinical Trials
- Treatment
- Diagnosis
- Neoadjuvant Therapy
- Cardiovascular Disease
- Treatment Guidelines
- Radiotherapy
- Pandemic
- ALK Inhibitors
- Molecular Characterization
- Cancer
- Biomarkers
- Surgical Complications
- Management
- Metastasis
- CT Screening
- SARS-CoV-2
- Regeneration
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology6▲ 2.9×32 topics
- Chemotherapy5▲ 14×10 topics
- Inflammation5▲ 4.2×24 topics
- Immunotherapy4▲ 10×9 topics
- Clinical Trials3▲ 8.1×5 topics
- Targeted Therapy3▲ 24×3 topics
- Treatment3▲ 4.4×16 topics
- Prognostic Factors3▲ 10×6 topics
- Diagnosis2▲ 4.3×12 topics
- Quality of Life2▲ 2.8×12 topics
- Neoadjuvant Therapy2▲ 16×4 topics
- Tumor Microenvironment2▲ 8.8×3 topics
- Cardiovascular Disease2▲ 3.3×13 topics
- Immune Response2▲ 6.4×6 topics
- Treatment Guidelines2▲ 17×4 topics
- Guidelines2▲ 7.0×9 topics
- Radiotherapy2▲ 8.8×3 topics
- Adjuvant Therapy2▲ 25×2 topics
- Pandemic2▲ 3.0×5 topics
- Surgical Management2▲ 7.6×6 topics
- ALK Inhibitors2▲ 47×1 topic
- EGFR Mutations2▲ 47×1 topic
- Molecular Characterization2▲ 17×4 topics
- Pathogenesis2▲ 5.9×9 topics
- Cancer2▲ 2.1×11 topics
- Pancreatic Cancer2▲ 25×2 topics
- Biomarkers2▲ 3.8×7 topics
- Gemcitabine2▲ 37×1 topic
- Surgical Complications2▲ 33×1 topic
- Diabetes1▲ 4.9×10 topics
- Management1▲ 3.0×6 topics
- Pathophysiology1▲ 8.4×5 topics
- Metastasis1▲ 6.7×4 topics
- Prognosis1▲ 6.8×6 topics
- CT Screening1▲ 32×1 topic
- Lung Cancer1▲ 13×1 topic
- SARS-CoV-21▲ 6.5×5 topics
- Thrombosis1▲ 6.8×3 topics
- Regeneration1▲ 9.0×4 topics
- Tumor Markers1▲ 22×2 topics
Which research topics does Kitasato University Medical Center publish most on?
By volume in 2022–2025: Lung Cancer Treatments and Mutations, Pancreatic and Hepatic Oncology Research, Lung Cancer Diagnosis and Treatment and Gallbladder and Bile Duct Disorders.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
- 2 Pancreatic and Hepatic Oncology Research Oncology 2 works
- 3 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 1 works
- 4 Gallbladder and Bile Duct Disorders Pulmonary and Respiratory Medicine 1 works
- 5 Lung Cancer Research Studies Oncology 1 works
- 6 COVID-19 Clinical Research Studies Infectious Diseases 1 works
- 7 Gastrointestinal Tumor Research and Treatment Gastroenterology 1 works
- 8 Long-Term Effects of COVID-19 Neurology 1 works
- 9 Gastric Cancer Management and Outcomes Pulmonary and Respiratory Medicine 1 works
- 10 COVID-19 and Mental Health Clinical Psychology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Kitasato University Medical Center's research output changed?
Output in 2018–2022 was 26% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Saitama
- Saitama University
- National Defense Medical College
- Dokkyo University
- Josai University
- Social Insurance Saitama Chuo Hospital
- Saitama International Medical Center
- Meikai University
- Saitama Cancer Center
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.